Summit Therapeutics (SMMT) Reports Q4 Loss of GBP0.04

Summit Therapeutics (NASDAQ: SMMT) reported Q4 EPS of (GBP0.04).

GUIDANCE

With the extension of the $100.0 million note, we updated our cash guidance such that we now have sufficient cash to operate into the first quarter of 2025. Our prior cash guidance was to have sufficient funds going into September 2024.

For earnings history and earnings-related data on Summit Therapeutics (SMMT) click here.

You May Also Be Interested In

• Summit Therapeutics plc (SMMT) PT Raised to $9.80 at Bernstein SocGen Group
• SPS Commerce hires Morgan Stanley to explore sale amid activist push - Reuters
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance